|
Glioblastoma Multiforme (GBM) – Pipeline Review, H1 2012
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
Zahlen und Fakten zur Studie: | 187 seiten | |||||||||
| Inhalt der Studie: |
Introduction
Global Markets Direct’s, 'Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2012', provides an overview of the Glioblastoma Multiforme (GBM) therapeutic pipeline. This report provides .....
Introduction Global Markets Direct’s, 'Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2012', provides an overview of the Glioblastoma Multiforme (GBM) therapeutic pipeline. This report provides information on the therapeutic development for Glioblastoma Multiforme (GBM), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glioblastoma Multiforme (GBM). 'Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Glioblastoma Multiforme (GBM). - A review of the Glioblastoma Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Glioblastoma Multiforme (GBM) pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Highlights Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Glioblastoma Multiforme (GBM). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players with the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) pipeline depth and focus of Glioblastoma Multiforme (GBM) therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. [Studien Infos ausblenden] |
|||||||||||
|
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 Glioblastoma Multiforme (GBM) Overview 12 Therapeutics Development 13 An Overview of Pipeline Products for Glioblastoma Multiforme (GBM) 13 Glioblastoma Multiforme (GBM) Therapeutics under Development by Companies 15 Glioblastoma Multiforme (GBM) Therapeutics under Investigation by Universities/Institutes 22 Late Stage Products 30 Comparative Analysis 30 Mid Clinical Stage Products 31 Comparative Analysis 31 Early Clinical Stage Products 32 Comparative Analysis 32 Discovery and Pre-Clinical Stage Products 33 Comparative Analysis 33 Glioblastoma Multiforme (GBM) Therapeutics – Products under Development by Companies 34 Glioblastoma Multiforme (GBM) Therapeutics – Products under Investigation by Universities/Institutes 41 Companies Involved in Glioblastoma Multiforme (GBM) Therapeutics Development 56 Bristol-Myers Squibb Company 56 Boehringer Ingelheim GmbH 57 F. Hoffmann-La Roche Ltd. 58 Amgen Inc. 59 Sanofi-Aventis 60 AstraZeneca PLC 61 Eli Lilly and Company 62 Daiichi Sankyo Company, Ltd 63 Merck & Co., Inc. 64 Lentigen Corporation 65 Sangamo BioSciences, Inc. 66 YM BioSciences Inc. 67 Ark Therapeutics Group plc 68 Millennium Pharmaceuticals, Inc. 69 Novartis AG 70 ImClone Systems Incorporated 71 Actelion Ltd 72 Eisai Co., Ltd. 73 Nippon Shinyaku Co., Ltd. 74 Pfizer Inc. 75 Cell Therapeutics, Inc. 76 Exelixis, Inc. 77 Aduro BioTech 78 Geron Corporation 79 Merck KGaA 80 Access Pharmaceuticals, Inc. 81 EntreMed, Inc. 82 Celldex Therapeutics, Inc. 83 ImmunoCellular Therapeutics, Ltd. 84 Lixte Biotechnology Holdings, Inc. 85 Northwest Biotherapeutics, Inc. 86 Circadian Technologies Limited 87 Oncolytics Biotech Inc. 88 Oncothyreon Inc 89 Peregrine Pharmaceuticals, Inc. 90 Pharmacyclics, Inc. 91 PhytoMedical Technologies, Inc. 92 Transgene SA 93 Threshold Pharmaceuticals, Inc. 94 Bradmer Pharmaceuticals Inc. 95 Proximagen Neuroscience plc. 96 Protox Therapeutics Inc. 97 Rexahn Pharmaceuticals, Inc. 98 INSYS Therapeutics, Inc. 99 Ambit Biosciences Corporation 100 Immupharma Plc 101 immatics biotechnologies GmbH 102 Apogenix GmbH 103 Indena S.p.A. 104 Oncolin Therapeutics, Inc. 105 Diffusion Pharmaceuticals LLC 106 Arno Therapeutics, Inc. 107 Reata Pharmaceuticals, Inc. 108 Vascular Biogenics Ltd. 109 BioCancell Therapeutics, Inc. 110 Axelar AB 111 Advenchen Laboratories, LLC 112 Myriad Pharmaceuticals, Inc. 113 NOXXON Pharma AG 114 BiPar Sciences, Inc. 115 ChemoCentryx, Inc. 116 TVAX Biomedical, LLC 117 Sirnaomics, Inc. 118 AVEO Pharmaceuticals, Inc. 119 Nexgenix Pharmaceuticals, LLC 120 Archer Biosciences, Inc 121 Direct Therapeutics, Inc. 122 R&D Systems, Inc. 123 TAU Therapeutics, LLC 124 CytomX, LLC. 125 Glioblastoma Multiforme (GBM) – Therapeutics Assessment 126 Assessment by Monotherapy Products 126 Assessment by Combination Products 127 Assessment by Route of Administration 128 Assessment by Molecule Type 131 Drug Profiles 134 Enzastaurin - Drug Profile 134 Product Description 134 Mechanism of Action 134 R&D Progress 134 Recentin - Drug Profile 136 Product Description 136 Mechanism of Action 136 R&D Progress 136 Rindopepimut - Drug Profile 137 Product Description 137 Mechanism of Action 137 R&D Progress 137 Avastin - Drug Profile 138 Product Description 138 Mechanism of Action 138 R&D Progress 138 Cilengitide - Drug Profile 140 Product Description 140 Mechanism of Action 140 R&D Progress 140 IL13-PE38QQR - Drug Profile 142 Product Description 142 Mechanism of Action 142 R&D Progress 142 Cerepro - Drug Profile 144 Product Description 144 Mechanism of Action 144 R&D Progress 144 Recentin + Lomustine - Drug Profile 146 Product Description 146 Mechanism of Action 146 R&D Progress 146 Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Methotrexate + Temozolomide + Thiotepa + Vincristine + Stem cell transplantation + Radiation Therapy - Drug Profile 147 Product Description 147 Mechanism of Action 147 R&D Progress 148 Cilengitide + Temozolomide + Radiotherapy - Drug Profile 150 Product Description 150 Mechanism of Action 150 R&D Progress 150 Avastin + Temozolomide + Radiation Therapy - Drug Profile 152 Product Description 152 Mechanism of Action 152 R&D Progress 152 Carmustine + O6-Benzylguanine + Radiation Therapy - Drug Profile 154 Product Description 154 Mechanism of Action 154 R&D Progress 154 O6-benzylguanine + Carmustine + Radiation therapy - Drug Profile 156 Product Description 156 Mechanism of Action 156 R&D Progress 156 Temozolomide - Drug Profile 158 Product Description 158 Mechanism of Action 158 R&D Progress 158 Temozolomide + Radiation Therapy - Drug Profile 159 Product Description 159 Mechanism of Action 159 R&D Progress 159 Temozolomide + Lomustine - Drug Profile 160 Product Description 160 Mechanism of Action 160 R&D Progress 160 Carboplatin + Temozolomide + Thiotepa + Vincristine + Stem Cell Transplantion + Radiation Therapy - Drug Profile 161 Product Description 161 Mechanism of Action 161 R&D Progress 162 Temodal + Radiation Therapy - Drug Profile 163 Product Description 163 Mechanism of Action 163 R&D Progress 163 Temozolomide - Drug Profile 164 Product Description 164 Mechanism of Action 164 R&D Progress 164 Glioblastoma Multiforme (GBM) Therapeutics – Drug Profile Updates 165 Glioblastoma Multiforme (GBM) Therapeutics – Discontinued Products 168 Glioblastoma Multiforme (GBM) Therapeutics - Dormant Products 170 Glioblastoma Multiforme (GBM) – Product Development Milestones 178 Featured News & Press Releases 178 Jan 11, 2012: Antisense Pharma To Pursue First-Line Treatment With Trabedersen, Terminates 2nd Line Phase III High Grade Glioma Trial 178 Jan 09, 2012: NW Bio Reaches 25 Clinical Trial Sites In Ongoing Clinical Trial Of DCVax 178 Jan 08, 2012: Circadian Commences First Phase I Clinical Trial Of VGX-100 In Cancer Patients 179 Dec 02, 2011: MDxHealth Enters Agreement With Celldex For Use Of MGMT Epigenetic Test In Phase III Rindopepimut Study In Brain Cancer 179 Dec 01, 2011: Celldex Initiates Pivotal International Phase III Trial Of Rindopepimut In Patients With Glioblastoma 180 Nov 21, 2011: Celldex Reports Positive Mature Survival Data From Rindopepimut Phase II Brain Cancer Study At SNO 2011 181 Nov 18, 2011: ImmunoCellular Therapeutics To Present Data On ICT-107 At 16th Annual Meeting Of Society For Neuro-Oncology 182 Nov 14, 2011: Lentigen And UH Case Medical Center Initiate Phase I Trial Using Gene Therapy And Bone Marrow Stem Cells In Treatment Of Brain Cancer 183 Oct 31, 2011: Celldex Therapeutics Receives Orphan Drug Designation In EU For Rindopepimut For Glioblastoma 184 Oct 31, 2011: Circadian Receives FDA IND Approval To Begin Clinical Trials With VGX-100 For Treatment Of Solid Tumors 185 Appendix 186 Methodology 186 Coverage 186 Secondary Research 186 Primary Research 186 Expert Panel Validation 187 Contact Us 187 Disclaimer 187 [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
List of Tables Number of Products Under Development for Glioblastoma Multiforme (GBM), H1 2012 13 Products under Development for Glioblastoma Multiforme (GBM) – Comparative Analysis, H1 2012 14 Number of Products under Development by Companies, H1 2012 16 Number of Products under Development by Companies, H1 2012 (Contd..1) 17 Number of Products under Development by Companies, H1 2012 (Contd..2) 18 Number of Products under Development by Companies, H1 2012 (Contd..3) 19 Number of Products under Development by Companies, H1 2012 (Contd..4) 20 Number of Products under Development by Companies, H1 2012 (Contd..5) 21 Number of Products under Investigation by Universities/Institutes, H1 2012 23 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 24 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 25 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 26 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 27 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 28 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 29 Comparative Analysis by Late Stage Development, H1 2012 30 Comparative Analysis by Mid Clinical Stage Development, H1 2012 31 Comparative Analysis by Early Clinical Stage Development, H1 2012 32 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 33 Products under Development by Companies, H1 2012 34 Products under Development by Companies, H1 2012 (Contd..1) 35 Products under Development by Companies, H1 2012 (Contd..2) 36 Products under Development by Companies, H1 2012 (Contd..3) 37 Products under Development by Companies, H1 2012 (Contd..4) 38 Products under Development by Companies, H1 2012 (Contd..5) 39 Products under Development by Companies, H1 2012 (Contd..6) 40 Products under Investigation by Universities/Institutes, H1 2012 41 Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 42 Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 43 Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 44 Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 45 Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 46 Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 47 Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 48 Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 49 Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 50 Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 51 Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 52 Products under Investigation by Universities/Institutes, H1 2012 (Contd..12) 53 Products under Investigation by Universities/Institutes, H1 2012 (Contd..13) 54 Products under Investigation by Universities/Institutes, H1 2012 (Contd..14) 55 Bristol-Myers Squibb Company, H1 2012 56 Boehringer Ingelheim GmbH, H1 2012 57 F. Hoffmann-La Roche Ltd., H1 2012 58 Amgen Inc., H1 2012 59 Sanofi-Aventis, H1 2012 60 AstraZeneca PLC, H1 2012 61 Eli Lilly and Company, H1 2012 62 Daiichi Sankyo Company, Ltd, H1 2012 63 Merck & Co., Inc., H1 2012 64 Lentigen Corporation, H1 2012 65 Sangamo BioSciences, Inc., H1 2012 66 YM BioSciences Inc., H1 2012 67 Ark Therapeutics Group plc, H1 2012 68 Millennium Pharmaceuticals, Inc., H1 2012 69 Novartis AG, H1 2012 70 ImClone Systems Incorporated, H1 2012 71 Actelion Ltd, H1 2012 72 Eisai Co., Ltd., H1 2012 73 Nippon Shinyaku Co., Ltd., H1 2012 74 Pfizer Inc., H1 2012 75 Cell Therapeutics, Inc., H1 2012 76 Exelixis, Inc., H1 2012 77 Aduro BioTech, H1 2012 78 Geron Corporation, H1 2012 79 Merck KGaA, H1 2012 80 Access Pharmaceuticals, Inc., H1 2012 81 EntreMed, Inc., H1 2012 82 Celldex Therapeutics, Inc., H1 2012 83 ImmunoCellular Therapeutics, Ltd., H1 2012 84 Lixte Biotechnology Holdings, Inc., H1 2012 85 Northwest Biotherapeutics, Inc., H1 2012 86 Circadian Technologies Limited, H1 2012 87 Oncolytics Biotech Inc., H1 2012 88 Oncothyreon Inc, H1 2012 89 Peregrine Pharmaceuticals, Inc., H1 2012 90 Pharmacyclics, Inc., H1 2012 91 PhytoMedical Technologies, Inc., H1 2012 92 Transgene SA, H1 2012 93 Threshold Pharmaceuticals, Inc., H1 2012 94 Bradmer Pharmaceuticals Inc., H1 2012 95 Proximagen Neuroscience plc., H1 2012 96 Protox Therapeutics Inc., H1 2012 97 Rexahn Pharmaceuticals, Inc., H1 2012 98 INSYS Therapeutics, Inc., H1 2012 99 Ambit Biosciences Corporation, H1 2012 100 Immupharma Plc, H1 2012 101 immatics biotechnologies GmbH, H1 2012 102 Apogenix GmbH, H1 2012 103 Indena S.p.A., H1 2012 104 Oncolin Therapeutics, Inc., H1 2012 105 Diffusion Pharmaceuticals LLC, H1 2012 106 Arno Therapeutics, Inc., H1 2012 107 Reata Pharmaceuticals, Inc., H1 2012 108 Vascular Biogenics Ltd., H1 2012 109 BioCancell Therapeutics, Inc., H1 2012 110 Axelar AB, H1 2012 111 Advenchen Laboratories, LLC, H1 2012 112 Myriad Pharmaceuticals, Inc., H1 2012 113 NOXXON Pharma AG, H1 2012 114 BiPar Sciences, Inc., H1 2012 115 ChemoCentryx, Inc., H1 2012 116 TVAX Biomedical, LLC, H1 2012 117 Sirnaomics, Inc., H1 2012 118 AVEO Pharmaceuticals, Inc., H1 2012 119 Nexgenix Pharmaceuticals, LLC, H1 2012 120 Archer Biosciences, Inc, H1 2012 121 Direct Therapeutics, Inc., H1 2012 122 R&D Systems, Inc., H1 2012 123 TAU Therapeutics, LLC, H1 2012 124 CytomX, LLC., H1 2012 125 Assessment by Monotherapy Products, H1 2012 126 Assessment by Combination Products, H1 2012 127 Assessment by Stage and Route of Administration, H1 2012 130 Assessment by Molecule Type, H1 2012 133 Glioblastoma Multiforme (GBM) Therapeutics – Drug Profile Updates 165 Glioblastoma Multiforme (GBM) Therapeutics – Discontinued Products 168 Glioblastoma Multiforme (GBM) Therapeutics – Discontinued Products (Contd..1) 169 Glioblastoma Multiforme (GBM) Therapeutics – Dormant Products 170 Glioblastoma Multiforme (GBM) Therapeutics – Dormant Products (Contd..1) 171 Glioblastoma Multiforme (GBM) Therapeutics – Dormant Products (Contd..2) 172 Glioblastoma Multiforme (GBM) Therapeutics – Dormant Products (Contd..3) 173 Glioblastoma Multiforme (GBM) Therapeutics – Dormant Products (Contd..4) 174 Glioblastoma Multiforme (GBM) Therapeutics – Dormant Products (Contd..5) 175 Glioblastoma Multiforme (GBM) Therapeutics – Dormant Products (Contd..6) 176 Glioblastoma Multiforme (GBM) Therapeutics – Dormant Products (Contd..7) 177 List of Figures Number of Products under Development for Glioblastoma Multiforme (GBM), H1 2012 13 Products under Development for Glioblastoma Multiforme (GBM) – Comparative Analysis, H1 2012 14 Products under Development by Companies, H1 2012 15 Products under Investigation by Universities/Institutes, H1 2012 22 Late Stage Products, H1 2012 30 Mid Clinical Stage Products, H1 2012 31 Early Clinical Stage Products, H1 2012 32 Discovery and Pre-Clinical Stage Products, H1 2012 33 Assessment by Monotherapy Products, H1 2012 126 Assessment by Combination Products, H1 2012 127 Assessment by Route of Administration, H1 2012 128 Assessment by Stage and Route of Administration, H1 2012 129 Assessment by Molecule Type, H1 2012 131 Assessment by Stage and Molecule Type, H1 2012 132 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
